Dibenzylxanthines as PPEPCK-M Inhibitors for Cancer Therapy
Marc Aragó,
Sergio Rodríguez-Arévalo,
Petra Hyrossova,
Juan Moreno,
Sònia Abás,
Agnès Figueras,
Belén Pérez,
Francesc Viñals,
María Carmen Escolano,
José Carlos Perales
Affiliations
Marc Aragó
Department of Physiological Sciences, Faculty of Medicine, University of Barcelona, 08907 L’Hospitalet de Llobregat, Spain
Sergio Rodríguez-Arévalo
Department of Pharmacology and Medicinal Chemistry, Faculty of Pharmacy, and Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain
Petra Hyrossova
Department of Physiological Sciences, Faculty of Medicine, University of Barcelona, 08907 L’Hospitalet de Llobregat, Spain
Juan Moreno
Department of Physiological Sciences, Faculty of Medicine, University of Barcelona, 08907 L’Hospitalet de Llobregat, Spain
Sònia Abás
Department of Pharmacology and Medicinal Chemistry, Faculty of Pharmacy, and Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain
Agnès Figueras
Institut D'Investigació Biomèdica de Bellvitge (IDIBELL), 08907 L’Hospitalet de Llobregat, Spain
Belén Pérez
Farmacologia Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
Francesc Viñals
Institut D'Investigació Biomèdica de Bellvitge (IDIBELL), 08907 L’Hospitalet de Llobregat, Spain
María Carmen Escolano
Department of Pharmacology and Medicinal Chemistry, Faculty of Pharmacy, and Institute of Biomedicine (IBUB), University of Barcelona, 08028 Barcelona, Spain
José Carlos Perales
Department of Physiological Sciences, Faculty of Medicine, University of Barcelona, 08907 L’Hospitalet de Llobregat, Spain
Phosphoenolpyruvate carboxykinase (PEPCK) is the key enzyme in gluconeogenesis/glyceroneogenesis, which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. [...]
